Oral heparin in the treatment of rheumatoid arthritis. 1995

J Imiela, and J Nosarzewski, and A Górski
Department of Internal Medicine II, Reilway Administration Central Hospital, Warsaw, Poland.

Heparin was administered orally in 10 patients with rheumatoid arthritis. The treatment resulted in clinical improvement in all cases (significant reduction in the number of tender and swollen joints and morning stiffness). This was associated with a decrease in erythrocyte sedimentation rate (8/10 patients) and cholesterol in all patients, although the differences were not significant. Recent data indicate that heparin can bind cytokines with potent immune modulatory action (e.g. TNF-alpha, interferon gamma etc.). Thus, neutralization of their action on target cells could be partially responsible for the beneficial effects reported. Moreover, heparin inhibits T cell traffic to a site of antigen by blocking enzymes digesting the extracellular matrix and interfering with selection activity. The results of our preliminary study suggest that heparin, given per os, may have immunomodulatory properties with potential application in human disease.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis

Related Publications

J Imiela, and J Nosarzewski, and A Górski
October 1977, Sovetskaia meditsina,
J Imiela, and J Nosarzewski, and A Górski
March 2002, Current drug targets. Inflammation and allergy,
J Imiela, and J Nosarzewski, and A Górski
March 1954, The Medical clinics of North America,
J Imiela, and J Nosarzewski, and A Górski
February 1998, Arthritis and rheumatism,
J Imiela, and J Nosarzewski, and A Górski
August 1983, Harefuah,
J Imiela, and J Nosarzewski, and A Górski
August 1996, British journal of rheumatology,
J Imiela, and J Nosarzewski, and A Górski
January 1979, Terapevticheskii arkhiv,
J Imiela, and J Nosarzewski, and A Górski
January 1998, Springer seminars in immunopathology,
J Imiela, and J Nosarzewski, and A Górski
November 1987, Annals of the rheumatic diseases,
Copied contents to your clipboard!